How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Similar Posts
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).
MHRA outlines intent to speed up patient access to innovative medical devices
Statement of Policy Intent sets out initial thinking on a new Early Access service to help patients benefit sooner from innovative medical devices that address unmet clinical needs.
Field Safety Notices: 14 to 18 July 2025
List of Field Safety Notices from 14 to 18 July 2025.
MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Siiltibcy
Guidance: Operational Information Sharing
Guidance for Marketing Authorisation (MA) applicants on providing consent to share operational information during the MA application process.
MHRA updates guidance on the Health Institution Exemption to support safe use of medical devices
Updated MHRA guidance will help health institutions, such as NHS Trusts and Boards, safely design and make general medical devices for patients.